nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FGF2—gestational diabetes	0.864	1	CbGaD
Sirolimus—ABCB1—Glyburide—gestational diabetes	0.0196	0.625	CbGbCtD
Sirolimus—CYP3A4—Glyburide—gestational diabetes	0.0117	0.375	CbGbCtD
Sirolimus—EIF4E—embryo—gestational diabetes	0.00547	0.133	CbGeAlD
Sirolimus—Allergic cutaneous angiitis—Glyburide—gestational diabetes	0.00459	0.108	CcSEcCtD
Sirolimus—EIF4E—uterus—gestational diabetes	0.00369	0.0898	CbGeAlD
Sirolimus—FGF2—islet of Langerhans—gestational diabetes	0.00345	0.0839	CbGeAlD
Sirolimus—Thrombocytopenic purpura—Glyburide—gestational diabetes	0.00311	0.073	CcSEcCtD
Sirolimus—Nephropathy—Glyburide—gestational diabetes	0.00307	0.0719	CcSEcCtD
Sirolimus—Kidney function abnormal—Glyburide—gestational diabetes	0.00302	0.0708	CcSEcCtD
Sirolimus—Leukocytoclastic vasculitis—Glyburide—gestational diabetes	0.00298	0.0698	CcSEcCtD
Sirolimus—EIF4E—head—gestational diabetes	0.00277	0.0674	CbGeAlD
Sirolimus—FGF2—uterus—gestational diabetes	0.00225	0.0547	CbGeAlD
Sirolimus—FGF2—adipose tissue—gestational diabetes	0.0022	0.0535	CbGeAlD
Sirolimus—MTOR—embryo—gestational diabetes	0.00212	0.0515	CbGeAlD
Sirolimus—FGF2—vagina—gestational diabetes	0.00183	0.0445	CbGeAlD
Sirolimus—Hyperbilirubinaemia—Glyburide—gestational diabetes	0.0016	0.0376	CcSEcCtD
Sirolimus—MTOR—uterus—gestational diabetes	0.00143	0.0347	CbGeAlD
Sirolimus—MTOR—adipose tissue—gestational diabetes	0.0014	0.034	CbGeAlD
Sirolimus—EIF4E—Leptin signaling pathway—LEPR—gestational diabetes	0.00139	0.0661	CbGpPWpGaD
Sirolimus—FKBP1A—uterus—gestational diabetes	0.00128	0.0312	CbGeAlD
Sirolimus—FKBP1A—adipose tissue—gestational diabetes	0.00126	0.0306	CbGeAlD
Sirolimus—Deafness—Glyburide—gestational diabetes	0.00118	0.0278	CcSEcCtD
Sirolimus—Hepatic failure—Glyburide—gestational diabetes	0.00118	0.0276	CcSEcCtD
Sirolimus—MTOR—vagina—gestational diabetes	0.00116	0.0282	CbGeAlD
Sirolimus—Renal impairment—Glyburide—gestational diabetes	0.00111	0.0261	CcSEcCtD
Sirolimus—SLC47A1—uterus—gestational diabetes	0.0011	0.0268	CbGeAlD
Sirolimus—Hypoglycaemia—Glyburide—gestational diabetes	0.00109	0.0254	CcSEcCtD
Sirolimus—SLC47A1—adipose tissue—gestational diabetes	0.00108	0.0263	CbGeAlD
Sirolimus—MTOR—head—gestational diabetes	0.00107	0.0261	CbGeAlD
Sirolimus—Hyponatraemia—Glyburide—gestational diabetes	0.00106	0.0249	CcSEcCtD
Sirolimus—FKBP1A—vagina—gestational diabetes	0.00104	0.0254	CbGeAlD
Sirolimus—FKBP1A—head—gestational diabetes	0.000964	0.0235	CbGeAlD
Sirolimus—Abdominal distension—Glyburide—gestational diabetes	0.000922	0.0216	CcSEcCtD
Sirolimus—Pancreatitis—Glyburide—gestational diabetes	0.000898	0.021	CcSEcCtD
Sirolimus—SLC47A1—vagina—gestational diabetes	0.000897	0.0218	CbGeAlD
Sirolimus—Pancytopenia—Glyburide—gestational diabetes	0.00087	0.0204	CcSEcCtD
Sirolimus—MTOR—Type II diabetes mellitus—ADIPOQ—gestational diabetes	0.000867	0.0412	CbGpPWpGaD
Sirolimus—CYP3A5—islet of Langerhans—gestational diabetes	0.000858	0.0209	CbGeAlD
Sirolimus—SLC47A1—head—gestational diabetes	0.000829	0.0202	CbGeAlD
Sirolimus—Visual impairment—Glyburide—gestational diabetes	0.000706	0.0166	CcSEcCtD
Sirolimus—MTOR—FSH signaling pathway—CYP19A1—gestational diabetes	0.000654	0.031	CbGpPWpGaD
Sirolimus—Malnutrition—Glyburide—gestational diabetes	0.000638	0.015	CcSEcCtD
Sirolimus—MTOR—AMPK Signaling—LEPR—gestational diabetes	0.000615	0.0292	CbGpPWpGaD
Sirolimus—Tremor—Glyburide—gestational diabetes	0.000598	0.014	CcSEcCtD
Sirolimus—Anaemia—Glyburide—gestational diabetes	0.00059	0.0138	CcSEcCtD
Sirolimus—Angioedema—Glyburide—gestational diabetes	0.000583	0.0137	CcSEcCtD
Sirolimus—MTOR—Leptin signaling pathway—LEPR—gestational diabetes	0.000575	0.0273	CbGpPWpGaD
Sirolimus—Leukopenia—Glyburide—gestational diabetes	0.000571	0.0134	CcSEcCtD
Sirolimus—CYP3A5—adipose tissue—gestational diabetes	0.000547	0.0133	CbGeAlD
Sirolimus—Myalgia—Glyburide—gestational diabetes	0.000543	0.0127	CcSEcCtD
Sirolimus—Arthralgia—Glyburide—gestational diabetes	0.000543	0.0127	CcSEcCtD
Sirolimus—Confusional state—Glyburide—gestational diabetes	0.000525	0.0123	CcSEcCtD
Sirolimus—Oedema—Glyburide—gestational diabetes	0.000521	0.0122	CcSEcCtD
Sirolimus—Shock—Glyburide—gestational diabetes	0.000512	0.012	CcSEcCtD
Sirolimus—Nervous system disorder—Glyburide—gestational diabetes	0.000511	0.012	CcSEcCtD
Sirolimus—Thrombocytopenia—Glyburide—gestational diabetes	0.00051	0.012	CcSEcCtD
Sirolimus—Hyperhidrosis—Glyburide—gestational diabetes	0.000503	0.0118	CcSEcCtD
Sirolimus—Anorexia—Glyburide—gestational diabetes	0.000496	0.0116	CcSEcCtD
Sirolimus—EIF4E—Leptin signaling pathway—LEP—gestational diabetes	0.00049	0.0232	CbGpPWpGaD
Sirolimus—Hypotension—Glyburide—gestational diabetes	0.000487	0.0114	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Glyburide—gestational diabetes	0.000474	0.0111	CcSEcCtD
Sirolimus—MTOR—SREBP signalling—RBP4—gestational diabetes	0.000474	0.0225	CbGpPWpGaD
Sirolimus—Paraesthesia—Glyburide—gestational diabetes	0.000468	0.011	CcSEcCtD
Sirolimus—Dyspnoea—Glyburide—gestational diabetes	0.000464	0.0109	CcSEcCtD
Sirolimus—Dyspepsia—Glyburide—gestational diabetes	0.000458	0.0107	CcSEcCtD
Sirolimus—ABCB1—islet of Langerhans—gestational diabetes	0.000456	0.0111	CbGeAlD
Sirolimus—CYP3A5—vagina—gestational diabetes	0.000455	0.0111	CbGeAlD
Sirolimus—Decreased appetite—Glyburide—gestational diabetes	0.000453	0.0106	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Glyburide—gestational diabetes	0.00045	0.0105	CcSEcCtD
Sirolimus—ABCB1—embryo—gestational diabetes	0.000441	0.0107	CbGeAlD
Sirolimus—Feeling abnormal—Glyburide—gestational diabetes	0.000429	0.0101	CcSEcCtD
Sirolimus—Gastrointestinal pain—Glyburide—gestational diabetes	0.000426	0.00998	CcSEcCtD
Sirolimus—Abdominal pain—Glyburide—gestational diabetes	0.000412	0.00965	CcSEcCtD
Sirolimus—EIF4E—PI3K Cascade—FGF2—gestational diabetes	0.000402	0.0191	CbGpPWpGaD
Sirolimus—Hypersensitivity—Glyburide—gestational diabetes	0.000384	0.00899	CcSEcCtD
Sirolimus—Asthenia—Glyburide—gestational diabetes	0.000374	0.00876	CcSEcCtD
Sirolimus—Pruritus—Glyburide—gestational diabetes	0.000368	0.00864	CcSEcCtD
Sirolimus—Diarrhoea—Glyburide—gestational diabetes	0.000356	0.00835	CcSEcCtD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—GCK—gestational diabetes	0.000351	0.0167	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—ADIPOQ—gestational diabetes	0.000348	0.0165	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—GGCT—gestational diabetes	0.000337	0.016	CbGpPWpGaD
Sirolimus—EIF4E—IRS-mediated signalling—FGF2—gestational diabetes	0.000337	0.016	CbGpPWpGaD
Sirolimus—Vomiting—Glyburide—gestational diabetes	0.000331	0.00776	CcSEcCtD
Sirolimus—Rash—Glyburide—gestational diabetes	0.000328	0.0077	CcSEcCtD
Sirolimus—Dermatitis—Glyburide—gestational diabetes	0.000328	0.00769	CcSEcCtD
Sirolimus—EIF4E—IRS-related events—FGF2—gestational diabetes	0.000327	0.0155	CbGpPWpGaD
Sirolimus—Headache—Glyburide—gestational diabetes	0.000326	0.00765	CcSEcCtD
Sirolimus—EIF4E—IRS-related events triggered by IGF1R—FGF2—gestational diabetes	0.000324	0.0154	CbGpPWpGaD
Sirolimus—EIF4E—IGF1R signaling cascade—FGF2—gestational diabetes	0.000316	0.015	CbGpPWpGaD
Sirolimus—EIF4E—Insulin receptor signalling cascade—FGF2—gestational diabetes	0.000316	0.015	CbGpPWpGaD
Sirolimus—Nausea—Glyburide—gestational diabetes	0.000309	0.00725	CcSEcCtD
Sirolimus—ABCB1—uterus—gestational diabetes	0.000297	0.00723	CbGeAlD
Sirolimus—ABCB1—adipose tissue—gestational diabetes	0.000291	0.00707	CbGeAlD
Sirolimus—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000272	0.0129	CbGpPWpGaD
Sirolimus—CYP3A7—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000269	0.0128	CbGpPWpGaD
Sirolimus—EIF4E—Signaling by Insulin receptor—FGF2—gestational diabetes	0.000262	0.0124	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—LEP—gestational diabetes	0.00025	0.0119	CbGpPWpGaD
Sirolimus—MTOR—Type II diabetes mellitus—TNF—gestational diabetes	0.000249	0.0118	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—GGCT—gestational diabetes	0.000244	0.0116	CbGpPWpGaD
Sirolimus—ABCB1—vagina—gestational diabetes	0.000242	0.00588	CbGeAlD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000236	0.0112	CbGpPWpGaD
Sirolimus—ABCB1—head—gestational diabetes	0.000223	0.00543	CbGeAlD
Sirolimus—CYP3A7—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000221	0.0105	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—gestational diabetes	0.000216	0.0103	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—LEP—gestational diabetes	0.000216	0.0102	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—LEP—gestational diabetes	0.000202	0.00958	CbGpPWpGaD
Sirolimus—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000197	0.00934	CbGpPWpGaD
Sirolimus—MTOR—Cardiac Hypertrophic Response—FGF2—gestational diabetes	0.000197	0.00933	CbGpPWpGaD
Sirolimus—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000194	0.00922	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—GCK—gestational diabetes	0.000188	0.00893	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000179	0.0085	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—GCK—gestational diabetes	0.000178	0.00846	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—TNF—gestational diabetes	0.000174	0.00826	CbGpPWpGaD
Sirolimus—MTOR—PI3K Cascade—FGF2—gestational diabetes	0.000166	0.00787	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CYP19A1—gestational diabetes	0.000165	0.00783	CbGpPWpGaD
Sirolimus—FGF2—Cardiac Hypertrophic Response—TNF—gestational diabetes	0.000161	0.00766	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—AR—gestational diabetes	0.00016	0.00761	CbGpPWpGaD
Sirolimus—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.00016	0.00757	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—FGF2—gestational diabetes	0.00014	0.00665	CbGpPWpGaD
Sirolimus—MTOR—IRS-mediated signalling—FGF2—gestational diabetes	0.000139	0.00659	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGF2—gestational diabetes	0.000138	0.00652	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—FGF2—gestational diabetes	0.000135	0.00641	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—FGF2—gestational diabetes	0.000134	0.00635	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—FGF2—gestational diabetes	0.00013	0.00618	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—FGF2—gestational diabetes	0.00013	0.00618	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	0.000129	0.00613	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—GCK—gestational diabetes	0.000126	0.00596	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—FGF2—gestational diabetes	0.000124	0.00588	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MBL2—gestational diabetes	0.000121	0.00575	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—FGF2—gestational diabetes	0.000121	0.00574	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—FGF2—gestational diabetes	0.00012	0.00569	CbGpPWpGaD
Sirolimus—MTOR—Cardiac Hypertrophic Response—TNF—gestational diabetes	0.00012	0.00568	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—GCK—gestational diabetes	0.000118	0.00559	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—CYP19A1—gestational diabetes	0.000117	0.00557	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGF2—gestational diabetes	0.000117	0.00556	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MBL2—gestational diabetes	0.000116	0.00549	CbGpPWpGaD
Sirolimus—CYP3A7—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000116	0.00549	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TNF—gestational diabetes	0.000116	0.00549	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—TNF—gestational diabetes	0.000115	0.00546	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GGCT—gestational diabetes	0.000113	0.00538	CbGpPWpGaD
Sirolimus—CYP3A4—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000113	0.00537	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—FGF2—gestational diabetes	0.000108	0.00514	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—LEPR—gestational diabetes	0.000103	0.00487	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ADIPOQ—gestational diabetes	9.7e-05	0.0046	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—LEP—gestational diabetes	9.63e-05	0.00457	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—FGF2—gestational diabetes	9.26e-05	0.00439	CbGpPWpGaD
Sirolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	9.16e-05	0.00434	CbGpPWpGaD
Sirolimus—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	9.03e-05	0.00429	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—FGF2—gestational diabetes	8.86e-05	0.0042	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—FGF2—gestational diabetes	8.72e-05	0.00414	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MBL2—gestational diabetes	8.59e-05	0.00408	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—gestational diabetes	8.53e-05	0.00405	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—CYP19A1—gestational diabetes	8.48e-05	0.00402	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—LEP—gestational diabetes	8.36e-05	0.00397	CbGpPWpGaD
Sirolimus—CYP3A5—Metapathway biotransformation—CYP19A1—gestational diabetes	8.36e-05	0.00397	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—FGF2—gestational diabetes	8.33e-05	0.00395	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—FGF2—gestational diabetes	8.29e-05	0.00393	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—RBP4—gestational diabetes	8.28e-05	0.00393	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—FGF2—gestational diabetes	8.25e-05	0.00391	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—FGF2—gestational diabetes	8.21e-05	0.00389	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MTNR1B—gestational diabetes	8.11e-05	0.00385	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGF2—gestational diabetes	8.09e-05	0.00384	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RBP4—gestational diabetes	7.91e-05	0.00375	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	7.86e-05	0.00373	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—FGF2—gestational diabetes	7.72e-05	0.00366	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—FGF2—gestational diabetes	7.72e-05	0.00366	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF2—gestational diabetes	7.72e-05	0.00366	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AR—gestational diabetes	7.71e-05	0.00366	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—FGF2—gestational diabetes	7.65e-05	0.00363	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—FGF2—gestational diabetes	7.58e-05	0.0036	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—FGF2—gestational diabetes	7.55e-05	0.00358	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LEPR—gestational diabetes	7.53e-05	0.00357	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NAMPT—gestational diabetes	7.43e-05	0.00352	CbGpPWpGaD
Sirolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	7.42e-05	0.00352	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—GCK—gestational diabetes	7.38e-05	0.0035	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—FGF2—gestational diabetes	7.14e-05	0.00339	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF2—gestational diabetes	6.84e-05	0.00324	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MBL2—gestational diabetes	6.74e-05	0.0032	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—GCK—gestational diabetes	6.38e-05	0.00303	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GGCT—gestational diabetes	6.28e-05	0.00298	CbGpPWpGaD
Sirolimus—FGF2—Disease—RBP4—gestational diabetes	6.28e-05	0.00298	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—LEP—gestational diabetes	6.02e-05	0.00286	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	5.96e-05	0.00283	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MTNR1B—gestational diabetes	5.95e-05	0.00282	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RBP4—gestational diabetes	5.8e-05	0.00275	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GGCT—gestational diabetes	5.77e-05	0.00274	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	5.72e-05	0.00272	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LEPR—gestational diabetes	5.71e-05	0.00271	CbGpPWpGaD
Sirolimus—FGF2—Disease—NAMPT—gestational diabetes	5.63e-05	0.00267	CbGpPWpGaD
Sirolimus—FGF2—Disease—GCK—gestational diabetes	5.59e-05	0.00265	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GLS2—gestational diabetes	5.49e-05	0.00261	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—FGF2—gestational diabetes	5.26e-05	0.0025	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GLS2—gestational diabetes	5.04e-05	0.00239	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MBL2—gestational diabetes	5e-05	0.00237	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	4.91e-05	0.00233	CbGpPWpGaD
Sirolimus—MTOR—Disease—RBP4—gestational diabetes	4.66e-05	0.00221	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTNR1B—gestational diabetes	4.51e-05	0.00214	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RBP4—gestational diabetes	4.39e-05	0.00209	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—FGF2—gestational diabetes	4.24e-05	0.00201	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEPR—gestational diabetes	4.23e-05	0.00201	CbGpPWpGaD
Sirolimus—MTOR—Disease—NAMPT—gestational diabetes	4.18e-05	0.00198	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GGCT—gestational diabetes	4.17e-05	0.00198	CbGpPWpGaD
Sirolimus—MTOR—Disease—GCK—gestational diabetes	4.15e-05	0.00197	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP19A1—gestational diabetes	3.94e-05	0.00187	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP19A1—gestational diabetes	3.89e-05	0.00184	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—gestational diabetes	3.86e-05	0.00183	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GLS2—gestational diabetes	3.64e-05	0.00173	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—LEP—gestational diabetes	3.6e-05	0.00171	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MTNR1B—gestational diabetes	3.35e-05	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RBP4—gestational diabetes	3.26e-05	0.00155	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GCK—gestational diabetes	3.2e-05	0.00152	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GGCT—gestational diabetes	3.14e-05	0.00149	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	3.13e-05	0.00148	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NAMPT—gestational diabetes	3.01e-05	0.00143	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—FGF2—gestational diabetes	3e-05	0.00142	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GCK—gestational diabetes	2.99e-05	0.00142	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—FGF2—gestational diabetes	2.88e-05	0.00137	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—FGF2—gestational diabetes	2.87e-05	0.00136	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—gestational diabetes	2.79e-05	0.00132	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NAMPT—gestational diabetes	2.76e-05	0.00131	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GLS2—gestational diabetes	2.75e-05	0.0013	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GCK—gestational diabetes	2.74e-05	0.0013	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—FGF2—gestational diabetes	2.74e-05	0.0013	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LEP—gestational diabetes	2.64e-05	0.00125	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP19A1—gestational diabetes	2.19e-05	0.00104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGF2—gestational diabetes	2.01e-05	0.000953	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP19A1—gestational diabetes	2.01e-05	0.000952	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LEP—gestational diabetes	2e-05	0.000951	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NAMPT—gestational diabetes	2e-05	0.000947	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GCK—gestational diabetes	1.98e-05	0.000941	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GGCT—gestational diabetes	1.94e-05	0.000919	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	1.9e-05	0.000903	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGF2—gestational diabetes	1.75e-05	0.000829	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLS2—gestational diabetes	1.69e-05	0.000803	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGF2—gestational diabetes	1.61e-05	0.000765	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NAMPT—gestational diabetes	1.51e-05	0.000715	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCK—gestational diabetes	1.5e-05	0.00071	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEP—gestational diabetes	1.49e-05	0.000705	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP19A1—gestational diabetes	1.45e-05	0.000688	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF2—gestational diabetes	1.13e-05	0.000536	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP19A1—gestational diabetes	1.09e-05	0.000519	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAMPT—gestational diabetes	9.28e-06	0.00044	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCK—gestational diabetes	9.22e-06	0.000437	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP19A1—gestational diabetes	6.74e-06	0.00032	CbGpPWpGaD
